Avalo Therapeutics Stock Forecast, Price & News

Avalo Therapeutics (NASDAQ:AVTX) Frequently Asked Questions

Is Avalo Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Avalo Therapeutics stock.
View analyst ratings for Avalo Therapeutics or view top-rated stocks.

Are investors shorting Avalo Therapeutics?

Avalo Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totaling 1,990,000 shares, an increase of 28.4% from the December 31st total of 1,550,000 shares. Based on an average daily trading volume, of 506,100 shares, the short-interest ratio is currently 3.9 days. Approximately 1.8% of the company's shares are sold short.
View Avalo Therapeutics' Short Interest.

When is Avalo Therapeutics' next earnings date?

Avalo Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022.
View our earnings forecast for Avalo Therapeutics.

How were Avalo Therapeutics' earnings last quarter?

Avalo Therapeutics Inc (NASDAQ:AVTX) posted its earnings results on Tuesday, November, 9th. The company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.01. The firm earned $1.35 million during the quarter. Avalo Therapeutics had a negative trailing twelve-month return on equity of 272.08% and a negative net margin of 1,211.01%.
View Avalo Therapeutics' earnings history.

What price target have analysts set for AVTX?

2 equities research analysts have issued 1 year price targets for Avalo Therapeutics' shares. Their forecasts range from $5.00 to $6.00. On average, they expect Avalo Therapeutics' share price to reach $5.50 in the next year. This suggests a possible upside of 541.5% from the stock's current price.
View analysts' price targets for Avalo Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Avalo Therapeutics' key executives?

Avalo Therapeutics' management team includes the following people:

• Michael F. Cola, Chief Executive Officer & Director
• Schond L. Greenway, Chief Financial Officer & Treasurer
• H. Jeffrey Wilkins, Chief Medical Officer
• Garry Arthur Neil, Chief Scientific Officer
• Younok Dumortier Shin, Chief Technology Officer

Who are some of Avalo Therapeutics' key competitors?

Some companies that are related to Avalo Therapeutics include VBI Vaccines (VBIV), PyroGenesis Canada (PYR), Y-mAbs Therapeutics (YMAB), 2seventy bio (TSVT), Aadi Bioscience (AADI), Adicet Bio (ACET), Zymeworks (ZYME), Evolus (EOLS), CytoDyn (CYDY), Xilio Therapeutics (XLO), DiaMedica Therapeutics (DMCAF), Spero Therapeutics (SPRO), Verona Pharma (VRNA), Affimed (AFMD) and ESSA Pharma (EPIX).
View all of AVTX's competitors.

What is Avalo Therapeutics' stock symbol?

Avalo Therapeutics trades on the NASDAQ under the ticker symbol "AVTX."

Who are Avalo Therapeutics' major shareholders?

Avalo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Strs Ohio (0.03%) and Minot Wealth Management LLC (0.03%). Company insiders that own Avalo Therapeutics stock include Armistice Capital, Llc, Christopher Ryan Sullivan, H Jeffrey Wilkins and Schond L Greenway.
View institutional ownership trends for Avalo Therapeutics.

Which major investors are selling Avalo Therapeutics stock?

AVTX stock was sold by a variety of institutional investors in the last quarter, including Minot Wealth Management LLC, and Strs Ohio.
View insider buying and selling activity for Avalo Therapeutics or view top insider-selling stocks.

How do I buy shares of Avalo Therapeutics?

Shares of AVTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avalo Therapeutics' stock price today?

One share of AVTX stock can currently be purchased for approximately $0.86.

How much money does Avalo Therapeutics make?

Avalo Therapeutics has a market capitalization of $96.30 million and generates $6.70 million in revenue each year.

How many employees does Avalo Therapeutics have?

Avalo Therapeutics employs 31 workers across the globe.

What is Avalo Therapeutics' official website?

The official website for Avalo Therapeutics is www.cerecor.com.

Where are Avalo Therapeutics' headquarters?

Avalo Therapeutics is headquartered at 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713.

How can I contact Avalo Therapeutics?

Avalo Therapeutics' mailing address is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. The company can be reached via phone at (410) 522-8707 or via email at [email protected].